Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground
Executive Summary
As Gilead’s ASK1 inhibitor nears Phase III, Intercept may be plagued by slower-than-expected enrollment of its Phase III trial for Ocaliva. A recent Biomedtracker survey finds liver docs may be more positively inclined toward the Gilead candidate.
You may also be interested in...
Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC
Although GS-9674’s efficacy data don’t appear as promising as that for Intercept’s competing FXR agonist OCA, Gilead seems to be building an argument that its drug has a better combination of efficacy and safety.
Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development
Combination therapy is expected to prevail in NASH. Pfizer and Novartis, while trailing smaller companies, are studying their candidates together in hopes of hitting on a winning combo for the multi-factorial disease.
New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib
Gilead presented early data for combinations of its three mechanisms in NASH, but analysts noted the findings may undercut its lead candidate selonsertib. Plus EASL takeaways for Genfit, NGM and Madrigal.